Compare ROAD & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROAD | RGEN |
|---|---|---|
| Founded | 2001 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.6B |
| IPO Year | 2018 | 1995 |
| Metric | ROAD | RGEN |
|---|---|---|
| Price | $111.87 | $111.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $127.80 | ★ $167.67 |
| AVG Volume (30 Days) | 495.5K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.46 | ★ 286.96 |
| EPS | ★ 0.47 | 0.15 |
| Revenue | ★ $785,679,000.00 | $141,236,000.00 |
| Revenue This Year | $27.79 | $14.30 |
| Revenue Next Year | $10.29 | $14.52 |
| P/E Ratio | ★ $234.17 | $724.87 |
| Revenue Growth | 0.31 | ★ 35.10 |
| 52 Week Low | $93.22 | $100.99 |
| 52 Week High | $151.00 | $175.77 |
| Indicator | ROAD | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 43.94 |
| Support Level | $102.84 | N/A |
| Resistance Level | $118.05 | $129.77 |
| Average True Range (ATR) | 6.63 | 6.03 |
| MACD | -2.47 | -1.08 |
| Stochastic Oscillator | 7.42 | 32.66 |
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.